Cue Biopharma (CUE) Competitors

Cue Biopharma logo
$4.15 -0.35 (-7.78%)
Closing price 04:00 PM Eastern
Extended Trading
$4.22 +0.07 (+1.69%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CUE vs. MDXG, KMDA, AVTE, AVTX, and ARVN

Should you buy Cue Biopharma stock or one of its competitors? Cue Biopharma's main competitors and comparable companies include MiMedx Group (MDXG), Kamada (KMDA), Aerovate Therapeutics (AVTE), Avalo Therapeutics (AVTX), and Arvinas (ARVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cue Biopharma compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

MiMedx Group has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

MiMedx Group has a net margin of -6.32% compared to Cue Biopharma's net margin of -579.95%. MiMedx Group's return on equity of 2.39% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
MiMedx Group-6.32% 2.39% 1.85%
Cue Biopharma -579.95%-620.87%-322.13%

In the previous week, Cue Biopharma had 7 more articles in the media than MiMedx Group. MarketBeat recorded 11 mentions for Cue Biopharma and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.35 beat Cue Biopharma's score of -0.09 indicating that MiMedx Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cue Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Cue Biopharma. MiMedx Group is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$418.63M1.08$48.58M-$0.13N/A
Cue Biopharma$27.47M1.21-$26.60M-$29.66N/A

MiMedx Group currently has a consensus target price of $8.14, suggesting a potential upside of 161.83%. Cue Biopharma has a consensus target price of $83.00, suggesting a potential upside of 1,718.18%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than MiMedx Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

MiMedx Group beats Cue Biopharma on 10 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Kamada?

Cue Biopharma (NASDAQ:CUE) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Kamada has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M1.21-$26.60M-$29.66N/A
Kamada$180.46M2.50$20.20M$0.4318.22

Cue Biopharma currently has a consensus price target of $83.00, suggesting a potential upside of 1,718.18%. Kamada has a consensus price target of $13.75, suggesting a potential upside of 75.52%. Given Cue Biopharma's higher possible upside, equities analysts clearly believe Cue Biopharma is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Kamada
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cue Biopharma had 8 more articles in the media than Kamada. MarketBeat recorded 11 mentions for Cue Biopharma and 3 mentions for Kamada. Kamada's average media sentiment score of 0.00 beat Cue Biopharma's score of -0.09 indicating that Kamada is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cue Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kamada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kamada has a net margin of 12.67% compared to Cue Biopharma's net margin of -579.95%. Kamada's return on equity of 9.36% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-579.95% -620.87% -322.13%
Kamada 12.67%9.36%6.53%

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cue Biopharma has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, Kamada has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Kamada beats Cue Biopharma on 11 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

35.0% of Cue Biopharma shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cue Biopharma had 11 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 11 mentions for Cue Biopharma and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Cue Biopharma's score of -0.09 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Cue Biopharma Neutral

Aerovate Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -579.95%. Aerovate Therapeutics' return on equity of -90.19% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Cue Biopharma -579.95%-620.87%-322.13%

Cue Biopharma has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Cue Biopharma$27.47M1.21-$26.60M-$29.66N/A

Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market.

Cue Biopharma has a consensus price target of $83.00, indicating a potential upside of 1,718.18%. Given Cue Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Cue Biopharma beats Aerovate Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cue Biopharma compare to Avalo Therapeutics?

Cue Biopharma (NASDAQ:CUE) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Cue Biopharma has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M1.21-$26.60M-$29.66N/A
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A

Avalo Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -579.95%. Avalo Therapeutics' return on equity of -34.21% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-579.95% -620.87% -322.13%
Avalo Therapeutics N/A -34.21%-29.84%

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cue Biopharma currently has a consensus price target of $83.00, suggesting a potential upside of 1,718.18%. Avalo Therapeutics has a consensus price target of $36.82, suggesting a potential upside of 445.45%. Given Cue Biopharma's higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Avalo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

Cue Biopharma has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Cue Biopharma had 8 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Cue Biopharma and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.34 beat Cue Biopharma's score of -0.09 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cue Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Avalo Therapeutics beats Cue Biopharma on 9 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Arvinas?

Cue Biopharma (NASDAQ:CUE) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Cue Biopharma presently has a consensus target price of $83.00, indicating a potential upside of 1,718.18%. Arvinas has a consensus target price of $15.18, indicating a potential upside of 125.25%. Given Cue Biopharma's higher probable upside, research analysts clearly believe Cue Biopharma is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Arvinas
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Cue Biopharma had 11 more articles in the media than Arvinas. MarketBeat recorded 11 mentions for Cue Biopharma and 0 mentions for Arvinas. Arvinas' average media sentiment score of 0.00 beat Cue Biopharma's score of -0.09 indicating that Arvinas is being referred to more favorably in the news media.

Company Overall Sentiment
Cue Biopharma Neutral
Arvinas Neutral

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arvinas has a net margin of -3.45% compared to Cue Biopharma's net margin of -579.95%. Arvinas' return on equity of -2.00% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-579.95% -620.87% -322.13%
Arvinas -3.45%-2.00%-1.43%

Cue Biopharma has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M1.21-$26.60M-$29.66N/A
Arvinas$262.60M1.68-$80.80M-$0.24N/A

Cue Biopharma has a beta of 2.79, meaning that its share price is 179% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Summary

Arvinas beats Cue Biopharma on 10 of the 15 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUE vs. The Competition

MetricCue BiopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$30.13M$3.92B$7.42B$10.86B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-0.1423.5332.4528.84
Price / Sales1.1015.598.085.38
Price / CashN/A22.6520.7221.66
Price / Book0.784.124.313.50
Net Income-$26.60M-$24.03M$3.51B$394.12M
7 Day Performance-74.26%-9.57%-7.89%-8.87%
1 Month Performance-75.65%-13.67%-10.43%-11.97%
1 Year Performance-99.15%-6.29%-2.77%-9.56%

Cue Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUE
Cue Biopharma
2.4133 of 5 stars
$4.15
-7.8%
$83.00
+1,900.0%
-99.1%$30.13M$27.47MN/A29
MDXG
MiMedx Group
2.6756 of 5 stars
$3.21
-1.1%
$8.14
+154.1%
-52.0%$467.71M$418.63MN/A808
KMDA
Kamada
4.9315 of 5 stars
$8.06
-0.8%
$13.75
+70.5%
+13.0%$463.76M$180.46M18.75462
AVTE
Aerovate Therapeutics
N/A$15.87
-4.1%
N/A+23.0%$459.99MN/AN/A20
AVTX
Avalo Therapeutics
4.0609 of 5 stars
$7.83
+1.7%
$36.82
+370.3%
-61.6%$453.31M$60KN/A33

Related Companies and Tools


This page (NASDAQ:CUE) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners